Can someone explain exactly what "rapamycin-sensitive oncogenic transformation" is? I get that it's a drug that suppresses the immune system but what does it have to do with oncogenic transformation?

Here's the article where they talk about it:


  • $\begingroup$ i am not particularly sure but it could be related to dysregulation of the mTOR pathway.. mTOR pathway is involved in survival in stress.. $\endgroup$
    May 23, 2013 at 13:05

1 Answer 1


The mammalian target of rapamycin (mTOR) is a Ser/Thr protein kinase that functions as an ATP and amino acid sensor to balance nutrient availability and cell growth. When sufficient nutrients are available, mTOR responds to a phosphatidic acid-mediated signal to transmit a positive signal to p70 S6 kinase and participate in the inactivation of the eIF4E inhibitor, 4E-BP1. These events result in the translation of specific mRNA subpopulations. mTOR is phosphorylated via the PI3 kinase/Akt signaling pathway and also autophosphorylates under translationally repressive conditions. mTOR plays a key role in cell growth and homeostasis and may be abnormally regulated in tumors. It is currently under investigation as a potential target for anti-cancer therapy.

The mTOR signaling pathway shows how mTOR is involved in numerous cell processes that can be dysregulated in cancer, including cell growth, proliferation, angiogenesis, autophagy, and various kinds of metabolism. "Rapamycin-sensitive oncogenic transformation" therefore means that the transformed cells still have intact "wild-type" mTOR complexes that can be down-regulated by the tumor-specific administration of rapamycin analogues, hence inhibiting the above-mentioned processes and arresting or killing the cells.


You must log in to answer this question.

Not the answer you're looking for? Browse other questions tagged .